Moreover, TGF-β signaling contributes to malignancy of cancer cells and immunosuppressive microenvironment, thus thwarting cancer immunotherapy (Colak and ten Dijke, 2017; Batlle and Massagué, 2019). This evidence concerns the gene TGFB1 and cancer.